Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis

Clinical Science

Volumn 105, Issue 1, 2003, Pages 1-8

  Ferguson, James Walter ^a   Therapondos, George ^a   Newby, David E ^a   Hayes, Peter Clive ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Antagonist; Aquaporin; Aquaretic; Cirrhosis; Vasopressin

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; 4 AMINOBUTYRIC ACID; ALCOHOL; ANGIOTENSIN; ASPARTIC ACID; ATRIAL NATRIURETIC FACTOR; CHOLECYSTOKININ; CONIVAPTAN; DESMOPRESSIN; DOPAMINE; FUROSEMIDE; GLUTAMINE; HISTAMINE; LIXIVAPTAN; MORPHINE; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; NEUROPEPTIDE Y; PEPTIDE HORMONE; PHENYTOIN; PROSTAGLANDIN DERIVATIVE; RELCOVAPTAN; SODIUM; SUBSTANCE P; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ASCITES; BLOOD PRESSURE; CLINICAL TRIAL; DIURESIS; EDEMA; GLOMERULUS FILTRATION; HEART FAILURE; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; LIVER CIRRHOSIS; NEUROHYPOPHYSIS; PATHOPHYSIOLOGY; PLASMA OSMOLALITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SODIUM BLOOD LEVEL; VASOPRESSIN BLOOD LEVEL; VASOPRESSIN RELEASE; WATER RETENTION;

ANIMALS; AZEPINES; BENZAMIDES; BENZAZEPINES; CONTROLLED CLINICAL TRIALS; DIURETICS; HEART FAILURE, CONGESTIVE; HOMEOSTASIS; HUMANS; INAPPROPRIATE ADH SYNDROME; LIVER CIRRHOSIS; MODELS, ANIMAL; MORPHOLINES; PIPERIDINES; QUINOLONES; RATS; RECEPTORS, VASOPRESSIN; SPIRO COMPOUNDS; VASOPRESSINS;

EID: 0037667061     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20030062     Document Type: Review

References (60)

1. Bichet, D., Szatalowicz, V., Chaimovitz, C. and Schrier, R. W. (1982) Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann. Intern. Med. 96, 413-417
2. Epstein, M. (1985) Derangements of renal water handling in liver-disease. Gastroenterology 89, 1415-1425
3. Imaizumi, T., Harada, S., Hirooka, Y., Masaki, H., Momohara, M. and Takeshita, A. (1992) Effects of OPC-21268, an orally effective vasopressin V1 receptor antagonist in humans. Hypertension 20, 54-58
4. Yamamura, Y., Ogawa, H., Yamashita, H. et al. (1992) Characterization of a novel aquaretic agent, opc-31260, as an orally effective, nonpeptide vasopressin v2-receptor antagonist. Br. J. Pharmacol. 105, 787-791
5. Robinson, A. G. and Fitzsimmons, M. D. (1993) Vasopressin homeostasis: coordination of synthesis, storage and release. Regul. Pept. 45, 225-230
6. Hardman, J. and Limbird, L. (2001) Goodman and Gilmour The Pharmacological Basis of Therapeutics, McGraw-Hill Medical Publishing, New York
7. Wong, L. L. and Verbalis, J. G. (2001) Vasopressin V2 receptor antagonists. Cardiovasc. Res. 51, 391-402
8. Zing, H. H., Bourque, C. W. and Bichet, D. G. (1998) Vasopressin and Oxytocin, Plenum Press, New York
9. Acher, R. (1993) Neurohypophysial peptide systems: processing machinery, hydroosmotic regulation, adaptation and evolution. Regul. Pept. 45, 1-13
10. Raymond, J. R. (1994) Hereditary and acquired defects in signaling through the hormone-receptor-G protein complex. Am. J. Physiol. 266, F163-F174
11. Birnbaumer, M. (2000) Vasopressin receptors. Trends Endocrinol. Metab. 11, 406-410
12. Kaufmann, J. E., Oksche, A., Wollheim, C. B., Gunther, G., Rosenthal, W. and Vischer, U. M. (2000) Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J. Clin. Invest. 106, 107-116
13. Agre, P. and Nielsen, S. (1996) The aquaporin family of water channels in kidney. Nephrologie 17, 409-415
14. Knepper, M. A. (1997) Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am. J. Physiol. 272, F3-F12
15. Hirsch, A. T., Dzau, V. J., Majzoub, J. A. and Creager, M. A. (1989) Vasopressin-mediated forearm vasodilation in normal humans - evidence for a vascular vasopressin v2 receptor. J. Clin. Invest. 84, 418-426
16. Suzuki, S., Takeshita, A., Imaizumi, T. et al. (1989) Biphasic forearm vascular responses to intraarterial arginine vasopressin. J. Clin. Invest. 84, 427-434
17. Tagawa, T., Imaizumi, T., Shiramoto, M., Endo, T., Hironaga, K. and Takeshita, A. (1995) V2 receptor-mediated vasodilation in healthy humans. J. Cardiovasc. Pharmacol. 25, 387-392
18. van Lieburg, A. F., Knoers, N. V., Monnens, L. A. and Smits, P. (1995) Effects of arginine vasopressin and 1-desamino-8-D-arginine vasopressin on forearm vasculature of healthy subjects and patients with a V2 receptor defect. J. Hypertens. 13, 1695-1700
19. Tagawa, T., Imaizumi, T., Endo, T. et al. (1993) Vasodilatory effect of arginine vasopressin is mediated by nitric oxide in human forearm vessels. J. Clin. Invest. 92, 1483-1490
20. Szatalowicz, V. L., Arnold, P. E., Chaimovitz, C., Bichet, D., Berl, T. and Schrier, R. W. (1981) Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N. Engl. J. Med. 305, 263-266
21. Arroyo, V., Claria, J., Salo, J. and Jimenez, W. (1994) Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin. Liver Dis. 14, 44-58
22. Gines, P., Abraham, W. T. and Schrier, R. W. (1994) Vasopressin in pathophysiological states. Semin. Nephrol. 14, 384-397
23. Epstein, M., Weitzman, R. E., Preston, S. and Denunzio, A. G. (1984) Relationship between plasma arginine vasopressin and renal water handling in decompensated cirrhosis. Miner. Electrolyte Metab. 10, 155-165
24. Padfield, P. L. and Morton, J. T. (1974) Application of a sensitive radioimmunoassay for plasma arginine vasopressin to pathological conditions in man. Clin. Sci. Mol. Med. 47, 16-17
25. Salerno, F., Delbo, A., Maggi, A. et al. (1994) Vasopressin release and water metabolism in patients with cirrhosis. J. Hepatol. 21, 822-830
26. Camps, J., Sola, J., Arroyo, V. et al. (1987) Temporal relationship between the impairment of free water excretion and antidiuretic hormone hypersecretion in rats with experimental cirrhosis. Gastroenterology 93, 498-505
27. Linas, S. L., Anderson, R. J., Guggenheim, S. J., Robertson, G. L. and Berl, T. (1981) Role of vasopressin in impaired water excretion in conscious rats with experimental cirrhosis. Kidney Int. 20, 173-180
28. Fogel, M. R., Knauer, C. M., Andres, L. L. et al. (1982) Continuous intravenous vasopressin in active upper gastrointestinal bleeding. Ann. Intern. Med. 96, 565-569
29. Ioannou, G., Doust, J. and Rockey, D. C. (2001) Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst. Rev., CD002147
30. Ortega, R., Gines, P., Uriz, J. et al. (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36, 941-948
31. Mannucci, P. M. (2000) Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia. 6 (Suppl. 1), 60-67
32. Nakamura, Y., Haneda, T., Osaki, J., Miyata, S. and Kikuchi, K. (2000) Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur. J. Pharmacol. 391, 39-48
33. Charles, C. J., Donald, R. A., Ikram, H., Prickett, T. and Richards, A. M. (1998) Arginine vasopressin V1-receptor antagonism in an ovine model of acute myocardial infarction. J. Cardiovasc. Pharmacol. 32, 777-782
34. Fraser, T. B., Turner, S. W., Wen, C., Li, M., Burrell, L. M. and Whitworth, J. A. (2000) Vasopressin V1a receptor antagonism does not reverse adrenocorticotrophin-induced hypertension in the rat. Clin. Exp. Pharmacol. Physiol. 27, 866-870
35. Thibonnier, M., Kilani, A., Rahman, M. et al. (1999) Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients. Hypertension 34, 1293-1300
36. Brouard, R., Laporte, V., Serradeil, L. G. et al. (1998) Safety, tolerability, and pharmacokinetics of SR 49059, a administration in healthy volunteers. Adv. Exp. Med. Biol. 449, 455-465
37. Clair, M. J., King, M. K., Goldberg, A. T. et al. (2000) Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure. J. Pharmacol. Exp. Ther. 293, 852-860
38. Mah, S. C., Opperman, J. R., Baum, H. P. and Hofbauer, K. G. (1988) Biologic response to chronic blockade of vasopressin receptors in Sprague-Dawley rats. J. Pharmacol. Exp. Ther. 245, 1021-1027
39. Dubb, J., Allison, N., Tatoian, D. et al. (1987) SK 101926 is an antidiuretic in man. Kidney Int. 31, 267
40. Manning, M., Przybylski, J. P., Olma, A. et al. (1987) No requirement of cyclic conformation of antagonists in binding to vasopressin receptors. Nature (London) 329, 839-840
41. Thibonnier, M. (1990) Vasopressin agonists and antagonists. Hormone Res. 34, 124-128
42. Albright, J. D., Reich, M. F., Delos Santos, E. G. et al. (1998) 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2, 1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J. Med. Chem. 41, 2442-2444
43. Serradeil-Le Gal, C. (1998) Nonpeptide antagonists for vasopressin receptors - pharmacology of SR 121463A, a new potent and highly selective V-2 receptor antagonist. Vasopressin Oxytocin 449, 427-438
44. Guyader, D., Patat, A., Ellis-Grosse, E. J. and Orczyk, G. P. (2002) Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 36, 1197-1205
45. Lacour, C., Galindo, G., Canals, F. et al. (2000) Aquaretic and hormonal effects of a vasopressin V-2 receptor antagonist after acute and long-term treatment in rats. Eur. J. Pharmacol. 394, 131-138
46. Yamamura, Y., Nakamura, S., Itoh, S. et al. (1998) OPC-41061, a highly potent human vasopressin V-2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther. 287, 860-867
47. Ohnishi, A., Orita, Y., Takagi, N. et al. (1995) Aquaretic effect of a potent, orally-active, nonpeptide V-2 antagonist in men. J. Pharmacol. Exp. Ther. 272, 546-551
48. Risvanis, J., Naitoh, M., Johnston, C. I. and Burrell, L. M. (1999) In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat. Eur. J. Pharmacol. 381, 23-30
49. Burnier, M., Fricker, A. F., Hayoz, D., Nussberger, J. and Brunner, H. R. (1999) Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur. J. Clin. Pharmacol. 55, 633-637
50. Udelson, J. E., Smith, W. B., Hendrix, G. H. et al. (2001) Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104, 2417-2423
51. Decaux, G. (2001) Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J. Lab. Clin. Med. 138, 18-21
52. Wong, F., Blei, A. T., Blendis, L. M. and Thuluvath, P. J. (2003) A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial. Hepatology 37, 182-191
53. Bosch-Marce, M., Poo, J. L., Jimenez, W. et al. (1999) Comparison of two aquaretic drugs (Niravoline and OPC-31260) in cirrhotic rats with ascites and water retention. J. Pharmacol. Exp. Ther. 289, 194-201
54. Jimenez, W., Serradeil-Le Gal, C., Ros, J. et al. (2000) Long-term aquaretic efficacy of a selective nonpeptide V-2-vasopressin receptor antagonist, SR121463, in cirrhotic rats. J. Pharmacol. Exp. Ther. 295, 83-90
55. Tsuboi, Y., Ishikawa, S., Fujisawa, G., Okada, K. and Saito, T. (1994) Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int. 46, 237-244
56. Gerbes, A. L., Guelberg, V., Decaux, G., Gross, P., Massien, C. and Djian, J. (1999) VPA-985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis - A double-blind placebo controlled multicenter trial. Hepatology 30, 1033
57. Inoue, T., Ohnishi, A., Matsuo, A. et al. (1996) Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in cirrhosis. Hepatology 23, T26
58. Cash, J. D., Gader, A. M. and da Costa, J. (1974) The release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-D-arginine vasopressin, angiotensin and oxytocin in man. Br. J. Haematol. 27, 363-364
59. Manucci, P. M., Abery, M., Nilsson, I. M. and Robertson, B. (1975) Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br. J. Haematol. 30, 81-93
60. Bernat, A., Hoffmann, P., Dumas, A., Serradeil-LeGal, C., Raufaste, D. and Herbert, J. M. (1997) V-2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. J. Pharmacol. Exp. Ther. 282, 597-602